RenovoRx (RNXT) Stock Price, News & Analysis

Company Overview

RenovoRx, Inc. is a clinical‐stage biopharmaceutical company focused on the development of targeted regional therapies for patients with solid tumors. The company’s proprietary technology platform, known as the RenovoPortal™ System, enables isolated, pressurized delivery of therapeutic agents directly to tumors in the liver, pancreas and other organs. By maximizing local drug concentration while limiting systemic exposure, RenovoRx aims to enhance antitumor activity and reduce off‐target toxicities compared with conventional intravenous chemotherapy.

The RenovoPortal System consists of a minimally invasive catheter and pump designed to temporarily occlude blood flow and infuse drugs under controlled pressure. RenovoRx has conducted multiple Phase I/II clinical trials evaluating the safety and efficacy of its platform combined with standard-of-care chemotherapeutics, including irinotecan‐based regimens, in patients with metastatic colorectal and pancreatic cancers. Preliminary data have demonstrated encouraging response rates and a manageable safety profile, supporting further development in larger studies.

Founded in 2015 and headquartered in Los Angeles, RenovoRx completed a business combination transaction in early 2021 and is traded on the NASDAQ under the symbol RNXT. The company’s leadership team is led by President and Chief Executive Officer William A. Burns, whose prior experience spans oncology drug development and interventional radiology. Supporting the executive team are professionals with backgrounds in clinical operations, regulatory affairs and medical affairs, working to advance ongoing trials in the United States and select international sites.

Looking ahead, RenovoRx plans to expand its clinical program into additional indications and explore potential combinations with immunotherapy and targeted agents. The company is also seeking strategic partnerships and investigations to extend its localized drug delivery approach to a broader range of solid tumors, positioning its platform as a versatile tool in precision oncology.

Key Stats

• Today's Range: $1.30 to $1.34
• 50-Day Range: $0.96 to $1.42
• 52-Week Range: $0.75 to $1.69
• Volume: 149,940 shs
• Average Volume: 100,148 shs
• Market Capitalization: $47.54 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.25
• Consensus Rating: Buy

RenovoRx Stock Analysis - MarketRank™

RenovoRx scored higher than 58% of companies evaluated by MarketBeat, and ranked 431st out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

RenovoRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

RenovoRx has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for RenovoRx are expected to decrease in the coming year, from ($0.40) to ($0.46) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of RenovoRx is -3.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of RenovoRx is -3.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

RenovoRx has a P/B Ratio of 6.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.39% of the float of RenovoRx has been sold short.

Short Interest Ratio / Days to Cover

RenovoRx has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in RenovoRx has recently decreased by 17.98%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

RenovoRx does not currently pay a dividend.

Dividend Growth

RenovoRx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.39% of the float of RenovoRx has been sold short.

Short Interest Ratio / Days to Cover

RenovoRx has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in RenovoRx has recently decreased by 17.98%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, RenovoRx insiders have bought more of their company's stock than they have sold. Specifically, they have bought $111,318.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 9.13% of the stock of RenovoRx is held by insiders.

Percentage Held by Institutions

Only 3.10% of the stock of RenovoRx is held by institutions.

RNXT Stock Analysis - Frequently Asked Questions

How have RNXT shares performed this year?

RenovoRx's stock was trading at $1.29 at the beginning of 2025. Since then, RNXT shares have increased by 0.8% and is now trading at $1.30.

How were RenovoRx's earnings last quarter?

RenovoRx, Inc. (NASDAQ:RNXT) posted its earnings results on Thursday, May, 15th. The company reported ($0.08) EPS for the quarter, hitting the consensus estimate of ($0.08). The firm earned $0.20 million during the quarter, compared to the consensus estimate of $0.23 million.
Read the conference call transcript.

When did RenovoRx IPO?

RenovoRx (RNXT) raised $18 million in an IPO on Thursday, August 26th 2021. The company issued 1,800,000 shares at $9.00-$11.00 per share. Roth Capital Partners and Maxim Group LLC acted as the underwriters for the IPO.

How do I buy shares of RenovoRx?

Shares of RNXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of RenovoRx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that RenovoRx investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), Bakkt (BKKT), NIO (NIO) and Phunware (PHUN).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/08/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RNXT
• CIK: 1574094
• Web: www.renovorx.com
• Phone: 650-284-4433
• Fax: 650-397-4433
• Employees: 6
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $7.25
• High Stock Price Target: $11.50
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +451.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.81 million
• Net Margins: N/A
• Pretax Margin: -4,232.50%
• Return on Equity: -119.58%
• Return on Assets: -88.01%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.07
• Quick Ratio: 9.07

Sales & Book Value

• Annual Sales: $240 thousand
• Price / Sales: 200.38
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.19 per share
• Price / Book: 6.92

Miscellaneous

• Outstanding Shares: 36,572,000
• Free Float: 33,233,000
• Market Cap: $48.09 million
• Optionable: Not Optionable
• Beta: 1.27